MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517070792 A) filed by Floating Knight Biotech Pte. Ltd., Singapore, on July 25, for 'mannuronate, guluronate and gulumannuronate tablet, capsule or ampoule formulation and method for its preparation.'
Inventor(s) include Mirshafiey, Abbas; and Lalander, Jacob.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to tablet, capsule and ampoule formulations for oral and/or injectable use, the formulation comprising -D-mannuronic acid or a-L-guluronic acid or a mixture of -D- mannuronic acid and a-L-guluronic acid, oligomers thereof, or pharmaceutically acceptable salts thereof, wherein the total amount of -D-mannuronic acid or a-L-guluronic acid, or their mixture, oligomers thereof, or pharmaceutically acceptable salts thereof is 10 wt.-% to 99.999 wt.-% based on the total weight of the tablet or capsule, or 20 wt.-% to 60 wt.-% based on the total weight of the ampoule formulation, wherein the tablet, capsule or ampoule formulation further comprises caffeic acid or a salt thereof, for example in powder form, preferably in an amount of 0.001 wt.-% to 1 wt.-%, more preferably 0.01 wt.-% to 0.5 wt.-%, more preferably 0.05 wt.-% to 0.3 wt.-%, based on the total weight of the tablet, capsule or ampoule formulation. Additionally, the invention relates to tablet, capsule and ampoule formulations for oral and/or injectable use, preferably as a supplement or medication, in a method for treating neurodegeneration, inflammatory reactions, pain, cancer, aging, diabetes, and/or cadiopathy, and methods for preparing such formulations."
The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/EP2023/087660.
Disclaimer: Curated by HT Syndication.
